Mi­graine mar­ket­ing wars? Ab­b­Vie, Bio­haven, Eli Lil­ly, Am­gen lead push for at­ten­tion in new­ly com­pet­i­tive space

For a long time, mi­graine suf­fer­ers were stuck with the same old med­i­cines and ad­vice. Try some trip­tans, change your di­et, maybe even see if a nar­cot­ic might help — but no ma­jor drug ad­vances to pre­vent or stop de­bil­i­tat­ing mi­graine episodes in al­most 30 years.

Fast for­ward to 2021. With sev­en new drug ap­provals in the past three years, the once-mori­bund mi­graine mar­ket is sud­den­ly com­pet­i­tive. That’s good news for pa­tients be­cause the new meds from Ab­b­Vie, Bio­haven, Eli Lil­ly, Am­gen, Te­va and Lund­beck of­fer a va­ri­ety of de­liv­ery meth­ods and few­er side ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER